HC Wainwright Rates Damora Therapeutics (DMRA) buy

HC Wainwright has reiterated its 'buy' rating on Damora Therapeutics and set a price target at $45, a 124.22% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 16, 2026, 11:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Damora Therapeutics, Inc. ($DMRA) "buy" with a $45 price target on June 11, 2026.

Since the rating, $DMRA is down 0.6% after 1 week, up 31.1% after 1 month and down 13.7% to date (from the $21.36 close on Jun 11, 2026).

DMRA Damora Therapeutics, Inc.

$18.44 -15.49% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reaffirmed its 'buy' rating on Damora Therapeutics (DMRA) and set a price target of $45 on June 11, 2026.
The stock is currently priced at $20.07, significantly below its 52-week high of $38.33, which indicates potential upside for investors.
The consensus among analysts remains strong, with a mean target price of about $44.67, suggesting confidence in the company's future prospects.

Get $DMRA trade alerts by text

We text you when insiders, Congress or big funds trade $DMRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Damora Therapeutics, Inc. alert may contain errors. Disclosures

Analysts Set New Price Targets

HC Wainwright has reiterated its 'buy' rating on Damora Therapeutics, Inc. (DMRA) and set a price target of $45. This update was released on June 11, 2026, reflecting the firm's continued confidence in the company's future potential.

Price Target Context

The current stock price of Damora Therapeutics is $20.07, which is well below the 52-week high of $38.33. This pricing suggests that there may be significant room for growth, keeping the target of $45 in mind. The company's strong pipeline of therapies for hematologic disorders is likely fueling this optimistic outlook.

Other Analysts' Opinions

Alongside HC Wainwright's rating, several other firms have provided their insights on Damora. On September 29, 2026, Wedbush reiterated its 'Outperform' rating with a price target of $40. Guggenheim maintained their 'Buy' rating with a more ambitious target of $60 on September 25, 2026. On July 30, 2026, Wedbush also increased its target to $40, reflecting a shift in confidence. Jefferies initiated coverage with a 'Buy' rating and a target of $50 on July 27, 2026, indicating a growing interest from analysts.

What Damora Therapeutics, Inc. Does

Damora Therapeutics focuses on developing therapies for hematologic disorders and operates primarily in Denmark and North America. Its lead product, DMR-001, targets specific mutations for treating essential thrombocythemia, while DMR-002 and DMR-003 are designed for a broader range of patients with mutCALR-related conditions. Founded in 2011 and headquartered in Waltham, MA, the company has a small team of seven employees.

What’s Next for Damora

Investors should keep an eye on the upcoming earnings report scheduled for November 5, 2026. The current analyst consensus remains supportive of Damora's potential for growth. As with all analyst ratings, it's essential to remember that they are based on assumptions about the company's future performance and could change based on new information.

12-month forecast